2-(4-N-Boc-哌嗪)苄基乙醇 | 179250-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-(4-N-Boc-哌嗪)苄基乙醇
• 英文名称: 1-tert-butoxycarbonyl-4-(2-(hydroxymethyl)phenyl)piperazine
• 英文别名: 4-(2-(hydroxymethyl)phenyl)piperazine-1-carboxylic acid tert-butyl ester；1-t-butoxycarbonyl-4-(2-hydroxymethylphenyl)-piperazine；4-(2-hydroxymethylphenyl)piperazine-1-carboxylic acid t-butyl ester；Tert-butyl 4-[2-(hydroxymethyl)phenyl]piperazine-1-carboxylate
• CAS: 179250-28-3
• 化学式: C₁₆H₂₄N₂O₃
• 分子量: 292.378
• InChiKey: MQZUQGHXDLMAKT-UHFFFAOYSA-N

物化性质

• 熔点：
  67 °C
• 沸点：
  440.9±45.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-N-Boc-哌嗪)苄基乙醇 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

  摘要：

  The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (K-i = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (K-i = 6600 nM). Sulfonamide 39 (K-i = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (K-i = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (K-i = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.

  DOI：

  10.1021/jm0304109
• 作为产物：
  描述：

  1-BOC-4-(2-羧基苯基)哌嗪 在 氮气 、 dimethyl sulfide borane 、 甲醇 、 crude product 、 乙酸乙酯 、 盐酸 、 Sodium sulfate-III 作用下， 以 四氢呋喃 为溶剂， 反应 1.58h， 以to yield the title compound (1.3 g) as a clear oil that的产率得到2-(4-N-Boc-哌嗪)苄基乙醇
  参考文献：
  名称：

  1-(2-phenoxymethylphenyl)piperazine compounds

  摘要：

  本发明涉及式I的化合物：其中a和R1至R6如规范中所定义，或其药学上可接受的盐。式I的化合物是血清素和去甲肾上腺素再摄取抑制剂。本发明还涉及包括这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。

  公开号：

  US09012460B2

文献信息

• Indol-3-y-carbonyl-piperidin and piperazin-derivatives
  申请人：Bissantz Caterina

  公开号：US20070027163A1

  公开（公告）日：2007-02-01

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哒-3-基甲酰哌啶和哌嗪衍生物，其由以下式I表示：其中残基R1至R3如本文所定义。该发明还涉及含有这种化合物的药物组合物，以及制备这些化合物和组合物的方法。该发明还涉及治疗痛经、高血压、慢性心力衰竭、抗利尿素过度分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists
  作者：David L. Gray、Wenjian Xu、Brian M. Campbell、Amy B. Dounay、Nancy Barta、Susan Boroski、Lynne Denny、Lori Evans、Nancy Stratman、Al Probert

  DOI：10.1016/j.bmcl.2009.10.014

  日期：2009.12

  including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening of NRI-active compounds for binding to the 5-HT1A receptor provided a series of thiomorpholinone hits with this dual activity profile. Several iterations of design, synthesis, and testing led to substituted piperidine diphenyl ethers which are potent NRIs with 5-HT1A partial agonist properties. In addition,

  这都是去甲肾上腺素再摄取抑制剂（NRI）和5-HT的化合物阿部分激动剂可具有治疗神经精神障碍包括注意力缺陷多动障碍（ADHD）和抑郁症的潜力。针对与5-HT 1A受体结合的NRI活性化合物的靶向筛选，提供了一系列具有这种双重活性特征的硫吗啉代酮。设计，合成和测试导致取代的哌啶二苯醚作为强力的NRI与5-HT1的若干次迭代一个部分激动剂性质。此外，这些分子的优化提供了对多巴胺（DAT）和5-羟色胺（SERT）再摄取转运蛋白具有NRI选择性的化合物。单胺和5-HT 1A 还介绍了从已开发的哌啶二苯醚系列中选择的化合物的体外功能活性。
• Substituted aryl piperazines as neurokinin antagonists
  申请人：Merck & Co., Inc.

  公开号：US05607936A1

  公开（公告）日：1997-03-04

  Disclosed are substituted aryl piperazines of Formula I ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis. In particular compounds of Formula I are shown to be neurokinin antagonists.

  本文披露了Formula I的取代芳基哌嗪化合物，是一种在治疗炎症性疾病、疼痛或偏头痛、哮喘和呕吐方面有用的快速激肽受体拮抗剂。特别是Formula I的化合物被证明是神经激肽拮抗剂。
• (2-苄基苯基)哌嗪衍生物及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN108299338B

  公开（公告）日：2021-09-28

  本发明公开了(2‑苄基苯基)哌嗪衍生物及其用途，以及包含该类化合物的药物组合物，它们可用于抑制5‑羟色胺再摄取。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在治疗中枢神经系统功能障碍，特别是情感障碍中的用途。
• 1-(2-PHENOXYMETHYLPHENYL)PIPERAZINE COMPOUNDS
  申请人：Stangeland Eric L.

  公开号：US20110172246A1

  公开（公告）日：2011-07-14

  The invention relates to compounds of formula I: where a, and R 1 through R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及式I的化合物：其中a和R1至R6如规范中所定义，或其药学上可接受的盐。式I的化合物是血清素和去甲肾上腺素再摄取抑制剂。本发明还涉及包含这种化合物的制药组合物；使用这种化合物的方法；以及制备这种化合物的过程和中间体。